Predictive biomarkers, such as PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T lymphocyte-associated antigen-4), are frequently used to assess the response of ICI in NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.